UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) saw a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 13,900 shares, an increase of 363.3% from the February 13th total of 3,000 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 92,400 shares, the days-to-cover ratio is presently 0.2 days.

UCB Stock Performance

Shares of UCBJY traded up $1.56 during midday trading on Wednesday, reaching $92.80. 26,542 shares of the stock were exchanged, compared to its average volume of 41,870. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. UCB has a twelve month low of $56.77 and a twelve month high of $106.60. The business’s 50-day moving average price is $97.56 and its 200 day moving average price is $95.23.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.